Holen Sie sich die Stockscreener-App
735.20
0.05%
0.39
Schlusskurs vom Vortag:
$734.81
Offen:
$740.5
24-Stunden-Volumen:
612.80K
Relative Volume:
0.83
Marktkapitalisierung:
$75.69B
Einnahmen:
$14.92B
Nettoeinkommen (Verlust:
$4.42B
KGV:
17.91
EPS:
41.0422
Netto-Cashflow:
$3.79B
1W Leistung:
-6.71%
1M Leistung:
-13.71%
6M Leistung:
-3.50%
1J Leistung:
+22.53%
1-Tages-Spanne:
$729.20
$742.50
1-Wochen-Bereich:
$726.02
$780.95
52-Wochen-Spanne:
$541.00
$859.34
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2026-03-06 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | BofA Securities | Underperform → Buy |
| 2025-12-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Eingeleitet | HSBC Securities | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent - MedCity News
Baird reiterates Regeneron stock rating on Sanofi collaboration By Investing.com - Investing.com Canada
Sanofi To Pay Regeneron Up To $8B In Immunology Alliance - Law360
REGN Maintained by Jefferies -- Price Target Raised to $930 - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $930.00 - MarketBeat
Sanofi Commits Up to $8 Billion to Expand Regeneron Alliance on Next-Gen Antibodies - finance.biggo.com
Regeneron stock after-hours at EUR 660.45: minus 1.31 percent versus prior close - AD HOC NEWS
Jefferies raises Regeneron stock price target to $930 on partnership By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals (REGN) Reports Promising Ubamatamab Tr - GuruFocus
Regeneron And Sanofi Announce A Win-Win Collaboration Expansion (NASDAQ:REGN) - Seeking Alpha
Regeneron Pharmaceuticals (REGN) Reports Promising Phase 1/2 Tri - GuruFocus
Why Regeneron (REGN) Stock Is Trading Lower Today - FinancialContent
Regeneron posts trial data for ovarian cancer therapy (REGN:NASDAQ) - Seeking Alpha
Regeneron Pharmaceuticals (REGN) Unveils Positive Phase 2 COURAG - GuruFocus
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Sanofi and Regeneron expand global alliance - The Pharma Letter
Regeneron Pharmaceuticals Says Ubamatamab Show 73% Objective Response Rate & 11-Month Median PFS In LGSOC Patients - TradingView
Sanofi to ‘ignite’ R&D in $8B deal with longstanding partner Regeneron - BioWorld News
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) - The Manila Times
Regeneron reports 73% response rate for ovarian cancer drug trial By Investing.com - Investing.com Canada
Sanofi, Regeneron broaden alliance to find their next Dupixent - Yahoo Finance
Patients in a small study had a median 11 months without ovarian cancer worsening on an experimental drug. - Stock Titan
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss - marketscreener.com
Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal - WSJ
BMO reiterates Regeneron stock Outperform on Sanofi deal expansion By Investing.com - Investing.com Canada
Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion - Benzinga
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion - MarketBeat
REGN: Expanded alliance targets next-gen type 2 medicines with equal cost/profit sharing and $8B in payments - TradingView
REGN Upgraded by Argus Research -- Price Target Announced at $85 - GuruFocus
Argus upgrades Regeneron stock to Buy with USD 850 target - AD HOC NEWS
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor - biospace.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Argus - MarketBeat
Upcoming Webinar Hosted by Xtalks: Inside Regeneron's Path to Scientific Intelligence and R&D Efficiency - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecasts - Yahoo Finance
Argus upgrades Regeneron stock rating to buy on Dupixent growth By Investing.com - Investing.com Canada
BreakingviewsCOMMENTARY: Sanofi’s Regeneron fix requires extra shot of M&A - reuters.com
Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo Finance
Sanofi and Regeneron expand immunology partnership to the tune of $8bn - Pharmaceutical Technology
Sanofi to invest up to $8bn to expand alliance with Regeneron - marketscreener.com
REGN Stock In Focus: Sanofi Expands Immunology Deal With $1B Upfront Payment And 4 New Antibodies - Stocktwits
Sanofi expands Regeneron partnership with up to $8 billion deal i - Global Banking & Finance Review
Sanofi Expands Collaboration with Regeneron in Immunology with $10 Billion Upfront Payment - GuruFocus
Regeneron, Sanofi expand alliance with $1 billion upfront deal By Investing.com - Investing.com Canada
Regeneron drug said to cut muscle loss when combined with Novo's semaglutide (REGN:NASDAQ) - Seeking Alpha
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion - Yahoo Finance
Sanofi and Regeneron Expand Antibody Collaboration - marketscreener.com
Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute - marketscreener.com
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies - The Manila Times
Regeneron and Sanofi Expand Long-Standing Collaboration to Add Next-Generation Long-Acting Immunology Antibodies in Deal Worth Up to $8 Billion - Quiver Quantitative
REGN: Expanded partnership targets next-gen immunology therapies, sharing costs, profits, and innovation - TradingView
Regeneron (REGN) Grants One-Time Performance Awards to CEO and CSO, Forms New Subsidiary - GuruFocus
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Regeneron Pharmaceuticals Inc-Aktie (REGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial |
Sep 03 '26 |
Sale |
857.39 |
1,131 |
969,708 |
12,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Option Exercise |
719.37 |
400 |
287,748 |
1,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Sale |
850.00 |
400 |
340,000 |
603 |
0.57%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):